Screening for Diabetic Retinopathy in Endocrinology Clinics by Using Handheld Cameras and Applying Artificial Intelligence Algorithms
Open accessAbstract
According to estimations of the World Health Organization (WHO), there are almost 500M people in the world that suffer from diabetes. Projections suggest this number will surpass 700M by 2045 with global prevalence surpassing 7%. This huge population, alongside people with pre-diabetics, is prone to develop diabetic retinopathy, the leading cause of vision loss in the working age. While early screening can help prevent most cases of vision loss caused by diabetic retinopathy, the vast majority of patients are not being screened periodically as the guidelines instruct. The challenge is to find a reliable and convenient method to screen patients so that efficacy in detection of referral diabetic retinopathy is sufficient while integration with the flow of care is smooth, easy, simple, and cost-efficient. In this research, we described a screening process for more-than-mild retinopathy through the application of artificial intelligence (AI) algorithms on images obtained by a portable, handheld fundus camera. 156 patients were screened for mtmDR indication. Four images were taken per patient, two macula centered and two optic disc centered. The 624 images were taken using the Optomed Aurora fundus camera and were uploaded using Optomed Direct-Upload. Fully blinded and independently, a certified, experienced ophthalmologist (contracted by Optomed and based in Finland) reviewed each patient to determine ground truth. Indications that are different than mtmDR were also documented by the ophthalmologist to meet exclusion criteria. Data was obtained from anonymized images uploaded to the cloud-based AEYE-DS system and analysis results from the AI algorithm were promptly returned to the users. Of the 156 patients, a certified ophthalmologist determined 100% reached sufficient quality of images for grading, and 36 had existing retinal diseases that fall under exclusion criteria, thus, 77% of the participants met the participation criteria. Of the remaining 120 patients, the AEYE-DS system determined that 2 patients had at least one insufficient quality image. AEYE-DS provided readings for each of the 118 remaining patients (98.3% of all patients). These were statistically compared to the output of the ground truth arm. The patient ground truth was defined as the most severe diagnosis from the four patient images; the ophthalmologist diagnosed 54 patients as mtmDR+ (45% prevalence). Of the 54 patients with referable DR, 50 were diagnosed and of the 64 mtmDR- patients, 61 were correctly diagnosed by the AI. In summary, the results of the study in terms of sensitivity and specificity were 92.6% and 95.3%, respectively. The results indicated accurate classification of diabetic patients that required referral to the ophthalmologist and those who did not. The results also demonstrated the potential of efficient screening and easy workflow integration into points of care such as endocrinology clinics.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In randomized clinical trials, LumineticsCore has shown to improve physician productivity.
“In randomized clinical trials, this system has shown to improve health equity in minorities26 and physician productivity,8 as well as demonstrated safety, efficacy, and equity in youth with diabetes.7”
From Autonomous Artificial Intelligence in Diabetic Retinopathy Testing—Lessons Learned on Successful Health System Adoption (2026) · cites this paper as [8]
The available passages contain only the article title and publication information (pp. A419–A420), not study findings. Searches for LumineticsCore, randomized trials, and physician productivity returned no passage addressing the attributed claim. (LLM, conf=0.72)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Still being checked.
Cited by
Sorted by citations
Rom, Y., Aviv, R., Ianchulev, T., & Dvey-Aharon, Z. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2022-001140 · Cited by 34 · see citing works
Self-citationTeng, C. W., Patel, S. D., Barkmeier, A. J., Liu, T. Y. A., Myung, D., Henderer, J., Liu, J., Hansen, E., & Al-Aswad, L. A. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2025.100935 · Cited by 23 · see citing works
Sen, A., Mohanraj, P. S., Laxmi, V., Ashique, S., Vasudevan, R., Aldahish, A. A., Velu, A., Das, A., Ehsan, I., Islam, A., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101305 · Cited by 13 · see citing works
Status of artificial intelligence in Pakistan and its implications in anesthesiology
Khan, M. I., Murtaza, R. S., Ali, M. H., Ashraf, M. S., Yazdani, S., & Yaseen, A. (2022) · Anaesthesia Pain & Intensive Care · doi:10.35975/apic.v26i1.1776 · Cited by 4 · see citing works
Au, S. C. L. (2023) · Journal of Ophthalmology and Advance Research · doi:10.46889/joar.2023.4202 · Cited by 4 · see citing works
Artificial Intelligence in Diabetic Retinopathy
Grzybowski, A. E., & Brona, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-83756-2_11 · Cited by 1 · see citing works
Kim, J., Nguyen, N. V., Soifer, M., Elnahry, A. G., Al-Nawaflh, M. Y., Hébert, M., Sen, H. N., Bellur, S., & Kodati, S. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.4.15
Autonomous AI for Diabetic Retinopathy Screening: Evidence, Regulation, and Health-System Fit
Mehta, K., Patel, L., & Shah, M. (2026) · Clinical eHealth · doi:10.1016/j.ceh.2026.07.001
- Authors
- Dvey-Aharon, Z., & Huhtinen, P.
- Affiliations
- AEYE Health, New York, NY, USA
- Optomed, Oulu, Finland
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2021-05-01
- Volume
- 5
- Issue
- Supplement_1
- Pages
- A419-A420
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC8090068
- OpenAlex
- W3159290433
- Cited by
- 8
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 1 · 2022: 2
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the Endocrine Society (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Health Research
- Keywords
- diabetic retinopathy, retinopathy screening, artificial intelligence, endocrinology clinic, retinopathy grading, image quality assessment, blindness prevention, cost-effectiveness, prediabetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review